Contributions
Abstract: PB1663
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
Multiple Myeloma is a malignant bone marrow disorder with plasma cell proliferation. The average survival is about 4 years. There are 19,900 new cases of Multiple Myeloma (MM) every year in the United States and 10,700 deaths from the disease annually. Multiple myeloma is about 1% of all cancers and about 10% of the hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is the most common form of the pre-cancerous stage of MM. MGUS is characterized by the absence of clinical symptoms and low fraction of a monoclonal antibody (less than 3 g/dl) In addition less than 10% of the plasma cells in the bone marrow.MGUS prevalence is 2-3 times higher in Afro-Americans. There are differences in disease presentation and epidemiology of MM and MGUS between patients from different ethnic groups (Caucasian, Afro-Americans and Asian.). the difference between the incidence of phenomena in different ethnic groups implies a genetic basis for the disease. In Israel it is estimated that 400 to 500 new cases of MM are diagnosed annually.
Aims
Various studies have been conducted around the world examining the relationship between ethnic origin and the prognosis of multiple myeloma by comparing different indicators such as the survival index. The survival index differs among MM patients depending on their ethnic origin. Thus, the treatment of multiple myeloma may be tailored based on their background and ethnicity. For instance, studies conducted in the United States compared Caucasians to African Americans and other ethnic groups such as Asians and Hispanics. These studies indicate that the prognosis differs between populations and show a relationship between survival rates and patients’ ethnicity. The aim of this study is to assess the relationship between ethnic origin and the prognosis of MM among various populations in Israel, particularly in the Galilee region
Methods
A retrospective study was performed in order to analyze the medical records of MM patients treated in the Galilee region, exploring the relationship between prognosis and ethnicity. For this purpose, data was collected from medical files of MM patients treated at Ziv medical center and Galilee Medical center between 2008-2018.Patients were divided according to their ethnicity and survival was compared between different ethnic groups. Statistical analysis: Statistics are described using averages and standard deviations, median, and range. Qualitative data was described through prevalence and percentages. Differences in measures between the ethnic groups were thought of by the T or ANOVA tests. Results with p<0.05 were considered statistically significant
Results
A mortality rate of 48.9%, was found in the study, regardless of population origin. There was no difference in PFS (progression free survival) and OS (overall survival) between the different ethnic groups. The stage of the disease at the time of diagnosis is lower in Jews compared to patients of Arab origin with statistical significance (p≤0.008),34% of the patients were diagnosed in Stage I, 70.6% of them were Jewish compared to 29.4% of patients of Arab origin. 51.4% of patients were diagnosed in advanced stage III disease were from Arab ethnicity versus 39.4% of all patients
Conclusion
There was no statistically significant difference in survival between populations of different ethnicity. A difference was found in the stage of the disease at the time of diagnosis. The patients of Arab origin were diagnosed at a more advanced stage than the patients of Jewish origin
Keyword(s):
Abstract: PB1663
Type: Publication Only
Session title: Myeloma and other monoclonal gammopathies - Clinical
Background
Multiple Myeloma is a malignant bone marrow disorder with plasma cell proliferation. The average survival is about 4 years. There are 19,900 new cases of Multiple Myeloma (MM) every year in the United States and 10,700 deaths from the disease annually. Multiple myeloma is about 1% of all cancers and about 10% of the hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is the most common form of the pre-cancerous stage of MM. MGUS is characterized by the absence of clinical symptoms and low fraction of a monoclonal antibody (less than 3 g/dl) In addition less than 10% of the plasma cells in the bone marrow.MGUS prevalence is 2-3 times higher in Afro-Americans. There are differences in disease presentation and epidemiology of MM and MGUS between patients from different ethnic groups (Caucasian, Afro-Americans and Asian.). the difference between the incidence of phenomena in different ethnic groups implies a genetic basis for the disease. In Israel it is estimated that 400 to 500 new cases of MM are diagnosed annually.
Aims
Various studies have been conducted around the world examining the relationship between ethnic origin and the prognosis of multiple myeloma by comparing different indicators such as the survival index. The survival index differs among MM patients depending on their ethnic origin. Thus, the treatment of multiple myeloma may be tailored based on their background and ethnicity. For instance, studies conducted in the United States compared Caucasians to African Americans and other ethnic groups such as Asians and Hispanics. These studies indicate that the prognosis differs between populations and show a relationship between survival rates and patients’ ethnicity. The aim of this study is to assess the relationship between ethnic origin and the prognosis of MM among various populations in Israel, particularly in the Galilee region
Methods
A retrospective study was performed in order to analyze the medical records of MM patients treated in the Galilee region, exploring the relationship between prognosis and ethnicity. For this purpose, data was collected from medical files of MM patients treated at Ziv medical center and Galilee Medical center between 2008-2018.Patients were divided according to their ethnicity and survival was compared between different ethnic groups. Statistical analysis: Statistics are described using averages and standard deviations, median, and range. Qualitative data was described through prevalence and percentages. Differences in measures between the ethnic groups were thought of by the T or ANOVA tests. Results with p<0.05 were considered statistically significant
Results
A mortality rate of 48.9%, was found in the study, regardless of population origin. There was no difference in PFS (progression free survival) and OS (overall survival) between the different ethnic groups. The stage of the disease at the time of diagnosis is lower in Jews compared to patients of Arab origin with statistical significance (p≤0.008),34% of the patients were diagnosed in Stage I, 70.6% of them were Jewish compared to 29.4% of patients of Arab origin. 51.4% of patients were diagnosed in advanced stage III disease were from Arab ethnicity versus 39.4% of all patients
Conclusion
There was no statistically significant difference in survival between populations of different ethnicity. A difference was found in the stage of the disease at the time of diagnosis. The patients of Arab origin were diagnosed at a more advanced stage than the patients of Jewish origin
Keyword(s):